Overview
Areas of Research/Interest
- Optimizing biomarker directed treatment for late-stage lung cancer
- Optimizing treatment for patients with lung cancer and brain metastases
- Finding novel targets in early and advanced stage lung cancer
- Optimizing access to health care in women and minorities facing lung cancer
Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Alirocumab plus cemiplimab in immuno-refractory metastatic NSCLC: A single-arm, multi-center, phase 2 study.
Conference Journal of Clinical Oncology · June 1, 2026 2619Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (NSCLC) patients. PCSK9 was shown in preclinical models to mediate cancer immunotherapy resistance and may serve as a novel immuno-inhibi ... Full text CiteAssessing the impact of PCSK9 inhibition in small cell lung cancer with novel DLL3-targeted bispecific T-cell engager therapy.
Conference Journal of Clinical Oncology · June 1, 2026 e20135Background: B-specific T-cell engagers (BiTEs) such as tarlatamab, have improved upon the efficacy and durability of response in small cell lung cancer (SCLC). However, an unmet need remains due to the known “immune-cold” microenvironment and immune ... Full text CiteFeasibility assessment of a global, anonymized, human-in-the-loop AI decision-support platform for oncology second opinions following a live demo at an international symposium.
Journal article Journal of Clinical Oncology · June 1, 2026 e13672Background: There are widespread disparities in access to rapid, expert-level second opinions worldwide. We assessed the feasibility and early adoption of an anonymized, human-in-the-loop AI decision-support platform (PrecisCa.AI) that analyzes cases ... Full text CiteRecent Grants
LIMITLESS: A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using Exablate focused ultrasound during the standard of care treatment of brain metastase
Clinical TrialPrincipal Investigator · Awarded by Florida International University · 2026 - 2031A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients with SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Plexium, Inc. · 2026 - 2031An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Clinical TrialPrincipal Investigator · Awarded by Henlius USA Inc. · 2025 - 2030View All Grants
Education
University of Queensland (Australia) ·
2017
M.D.